Search

Author/Creator Machacek, Matthias

1. Half-life extension and non-human primate pharmacokinetic safety studies of i-body AD-114 targeting human CXCR4. Issue 7 (3rd October 2019)

Authors:
Griffiths, Katherine; Binder, Uli; McDowell, William; Tommasi, Rita; Frigerio, Mark; Darby, William G.; Hosking, Chris G.; Renaud, Lionel; Machacek, Matthias; Lloyd, Peter; Skerra, Arne; Foley, Michael
Journal:
MAbs
Issue:
Volume 11:Issue 7(2019)
Page Start:
1331
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. P7.09: Population Model Confirms Predictable Pharmacokinetic (PK) And Pharmacodynamic (PD) Profile for Apraglutide: Data From Two Randomized Phase 1 Studies. (13th September 2022)

Authors:
Bolognani, Federico; Machacek, Matthias; Kruithof, Annelieke; de Kam, Marieke; Bergmann, Kirsten; van Gent, Max; Moerland, Matthias; Crenn, Pascal; Meyer, Christian; Greig, Gerard; Gal, Pim; Schulthess, Pascal
Journal:
Transplantation
Issue:
Volume 106: Supplement 9S (2022)
Page Start:
S544
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. Population Pharmacokinetic/Pharmacodynamic Modeling of Glenzocimab (ACT017) a Glycoprotein VI Inhibitor of Collagen‐Induced Platelet Aggregation. (4th June 2020)

Authors:
Renaud, Lionel; Lebozec, Kristell; Voors‐Pette, Christine; Dogterom, Peter; Billiald, Philippe; Jandrot Perrus, Martine; Pletan, Yannick; Machacek, Matthias
Journal:
Journal of clinical pharmacology
Issue:
Volume 60:Number 9(2020)
Page Start:
1198
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗